|
<p align=justify>Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------------<p>Sales +4.5% to EUR 382.1m Profit after tax +81.9% to EUR 36.2m Successfully continued development pipeline<p>Between January and June 2001, sales of the Schwarz Pharma Group rose by 4.5% to a volume of EUR 382.1m. Gross Profit increased by 9% to EUR 233.9m.<p>Operating profit for the 1st half year of 2001 amounted to EUR 12.4m despite an increase in research & development expense by 31.5% to EUR 46.8m. More than 90% of the operating profit was generated in the 2nd quarter. A non-recurring gain increased non-operating income to EUR 49.3m. A pre-tax result of EUR 60.7m (+105.8%) was therefore achieved. The result after tax was EUR 36.2m (+81.9%), or EUR 1.65 per share.<p>For the fiscal year 2001 the Executive Board expects a sales increase by 3-4%. The operating result is expected to be improved further. The net profit excluding the mentioned non-recurring item will be 15% higher than in 2000. Net profit including the non-recurring item is expected to more than double.<p>In the first six months of the year Schwarz Pharma has successfully continued to develop all pipeline projects. Phase III study program for Rotigotine CDS, the Parkinson patch will begin in fall 2001. Clinical studies of phase IIb for SPM 907 against urinary urge incontinence will start in late September.<p>You will find more information in the internet: www.schwarzpharma.com or phone +49-(0)2173-48-1866<p> end of ad hoc announcement (c) DGAP 01.08.2001<p>Issuer`s information/explanatory remarks concerning this ad hoc announcement:<p>"We are satisfied with the performance of the second quarter 2001," says Patrick Schwarz-Schütte, Chief Executive Officer of Schwarz Pharma AG. "We increased our operating result in the second quarter by 12 percent. It represents more than 90 percent of operating profit for the half year. This trend will continue: We are forecasting further improvement in the operating result. For the 2001 financial year, we expect sales to increase by between three and four percent. Enhanced by a considerably improved operating result, we anticipate an underlying 15% increase in net income for the year 2001 without extraordinary events. If the non-recurring gain recorded in the second quarter is taken into account, the net income for 2001 is estimated to more than double." "We are pleased that Prof. Dr. Iris Löw-Friedrich starts today at Schwarz Pharma AG. She brings along intensive drug development experience and together with the team she will promote our development pipeline."<p>-------------------------------------------------------------------------------- WKN: 722190; Index: MDAX Listed: Amtlicher Handel in Düsseldorf und Frankfurt; Freiverkehr in Berlin, Bremen, Hamburg, München und Stuttgart<p> 010801 Aug 01<p><br><br>Autor: DGAP import (),08:05 01.08.2001</p> |
|
| aus der Diskussion: | DGAP-Ad hoc: Schwarz Pharma AG <DE0007221905> english = |
| Autor (Datum des Eintrages): | ad_hoc (01.08.01 08:05:09) |
| Beitrag: | 1 von 1 (ID:4097960) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |